Triglav Investments D.O.O. Has $7.69 Million Position in AstraZeneca PLC $AZN

Triglav Investments D.O.O. boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,199 shares of the company’s stock after purchasing an additional 11,217 shares during the period. Triglav Investments D.O.O.’s holdings in AstraZeneca were worth $7,687,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. NewSquare Capital LLC grew its position in AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. Richardson Financial Services Inc. increased its position in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after purchasing an additional 149 shares during the period. Rakuten Investment Management Inc. acquired a new position in shares of AstraZeneca in the third quarter valued at $31,000. FSA Wealth Management LLC raised its stake in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares in the last quarter. Finally, VSM Wealth Advisory LLC acquired a new position in AstraZeneca in the second quarter worth about $33,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a research note on Friday, January 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price target on shares of AstraZeneca in a research note on Wednesday, December 3rd. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Jefferies Financial Group began coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $187.68 on Thursday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $97.93 and a 200-day moving average price of $86.84. The company has a market cap of $582.15 billion, a price-to-earnings ratio of 62.35, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $192.79.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the previous year, the firm earned $2.08 EPS. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.